Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Klementiev, Boris ^a   Li, Shizhong ^a   Korshunova, Irina ^a   Dmytriyeva, Oksana ^a   Pankratova, Stanislava ^a   Walmod, Peter S ^a   Kjær, Laura K ^a   Dahllöf, Mattias S ^a   Lundh, Morten ^a   Christensen, Dan P ^a   Mandrup Poulsen, Thomas ^a,b   Bock, Elisabeth ^a   Berezin, Vladimir ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Amyloid ; Antagonistic peptide; Experimental autoimmune encephalitis; Inflammation; Interleukin 1; LPS; Pancreatic islets

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; SERYLGLYCYLARGINYLLYSYLSERYLSERYLLYSYLMETHIONYLGLUTAMINYLALANINE; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTHRITIS; ARTICLE; BLOOD BRAIN BARRIER; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG RECEPTOR BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; IMMUNOREGULATION; IN VITRO STUDY; MACROPHAGE; MALE; MEMORY DISORDER; NERVOUS SYSTEM INFLAMMATION; NEWBORN; NONHUMAN; PANCREAS ISLET CELL; RAT; REPORTER GENE; SOCIAL BEHAVIOR; SURFACE PLASMON RESONANCE;

ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; ARTHRITIS; CELLS, CULTURED; CEREBELLUM; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LIPOPOLYSACCHARIDES; MALE; NEURONS; OLIGOPEPTIDES; RATS; RATS, WISTAR; SOCIAL BEHAVIOR; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893979201     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-27     Document Type: Article

References (56)

1. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012, 11:633-652. 10.1038/nrd3800, 3644509, 22850787.
2. Sims JE, Gayle MA, Slack JL, Alderson MR, Bird TA, Giri JG, Colotta F, Re F, Mantovani A, Shanebeck K, Grabstein KH, Dower SK. Interleukin 1 signaling occurs exclusively via the type I receptor. Proc Natl Acad Sci USA 1993, 90:6155-6159. 10.1073/pnas.90.13.6155, 46886, 8327496.
3. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, Armes LG, Sommer A, Eisenberg SP, Thompson RC. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990, 343:336-340. 10.1038/343336a0, 2137200.
4. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
5. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, Hanrahan PS, Kraishi MM, Patel A, Sun G, Bear MB, 990145 Study Group A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004, 63:1062-1068. 10.1136/ard.2003.016014, 1755108, 15082469, 990145 Study Group.
6. Dinarello CA. A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol 2011, 41:1203-1217. 10.1002/eji.201141550, 21523780.
7. Skinner RA, Gibson RM, Rothwell NJ, Pinteaux E, Penny JI. Transport of interleukin-1 across cerebromicrovascular endothelial cells. Br J Pharmacol 2009, 156:1115-1123. 10.1111/j.1476-5381.2008.00129.x, 2697691, 19298391.
8. Dantzer R, Bluthé RM, Gheusi G, Cremona S, Layé S, Parnet P, Kelley KW. Molecular basis of sickness behavior. Ann NY Acad Sci 1998, 856:132-138. 10.1111/j.1749-6632.1998.tb08321.x, 9917873.
9. Rønn LCB, Olsen M, Østergaard S, Kiselyov V, Berezin V, Mortensen MT, Lerche MH, Jensen PH, Soroka V, Saffell JL, Doherty P, Poulsen FM, Bock E, Holm A. Identification of a neuritogenic ligand of the neural cell adhesion molecule using a combinatorial library of synthetic peptides. Nat Biotechnol 1999, 17:1000-1005. 10.1038/13697, 10504702.
10. Schousboe A, Frandsen A, Drejer J. Evidence for evoked release of adenosine and glutamate from cultured cerebellar granule cells. Neurochem Res 1989, 14:871-875. 10.1007/BF00964817, 2574422.
11. Brunstedt J. Rapid isolation of functionally intact pancreatic islets from mice and rats by Percoll gradient centrifugation. Diabetes Metab 1980, 6:87-89.
12. Humphreys DT, Wilson MR. Modes of L929 cell death induced by TNF-α and other cytotoxic agents. Cytokine 1999, 11:773-782. 10.1006/cyto.1998.0492, 10525316.
13. Lundh M, Christensen DP, Rasmussen DN, Mascagni P, Dinarello CA, Billestrup N, Grunnet LG, Mandrup-Poulsen T. Lysine deacetylases are produced in pancreatic β cells and are differentially regulated by proinflammatory cytokines. Diabetologica 2010, 53:2569-2578.
14. Køhler LB, Soroka V, Korshunova I, Berezin V, Borck E. A peptide derived from a trans-homophilic binding site in neural cell adhesion molecule induces neurite outgrowth and neuronal survival. J Neurosci Res 2010, 88:2165-2176. 10.1002/jnr.22380, 20209630.
15. Pankratova S, Kiryushko D, Sonn K, Soroka V, Køhler LB, Rathje M, Gu B, Gotfryd K, Clausen O, Zharkovsky A, Bock E, Berezin V. Neuroprotective properties of a novel, non-haematopoietic agonist of the erythropoietin receptor. Brain 2010, 133:2281-2294. 10.1093/brain/awq101, 20435631.
16. Hudson LC, Hughes CS, Bold-Fletcher NO, Vaden SL. Cerebrospinal fluid collection in rats: modification of a previous technique. Lab Anim Sci 1994, 44:358-361.
17. Smith CP, Bores GM, Petko W, Li M, Selk DE, Rush DK, Camacho F, Winslow JT, Fishkin R, Cunningham DM, Brooks KM, Roehr J, Hartman HB, Davis L, Vargas HM. Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. J Pharmacol Exp Ther 1997, 280:710-720.
18. van Kampen M, Selbach K, Schneider R, Schiegel E, Boess F, Schreiber R. AR-R 17779 improves social recognition in rats by activation of nicotinic α7 receptors. Psychopharmacology (Berl) 2004, 172:375-383. 10.1007/s00213-003-1668-7, 14727003.
19. Schreuder H, Tardif C, Trump-Kallmeyer S, Soffientini A, Sarubbi E, Akeson A, Bowlin T, Yanofsky S, Barrett RW. A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 1997, 386:194-200. 10.1038/386194a0, 9062194.
20. Brown KD, Claudio E, Siebenlist U. The roles of the classical and alternative nuclear factor-κB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther 2008, 10:212. 10.1186/ar2457, 2575629, 18771589.
21. Dinarello CA. Proinflammatory cytokines. Chest 2000, 118:503-508. 10.1378/chest.118.2.503, 10936147.
22. Gabay C. Cytokine inhibitors in the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2002, 2:135-149. 10.1517/14712598.2.2.135, 11849114.
23. McColl BW, Rothwell NJ, Allan SM. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci 2007, 27:4403-4412. 10.1523/JNEUROSCI.5376-06.2007, 17442825.
24. Vezzani A, Moneta D, Conti M, Richichi C, Ravizza T, De Luigi A, De Simoni MG, Sperk G, Andell-Jonsson S, Lundkvist J, Iverfeldt K, Bartfai T. Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proc Natl Acad Sci USA 2000, 97:11534-11539. 10.1073/pnas.190206797, 17235, 11016948.
25. Tehranian R, Andell-Jonsson S, Beni SM, Yatsiv I, Shohami E, Bartfai T, Lundkvist J, Iverfeldt K. Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. J Neurotrauma 2002, 19:939-951. 10.1089/089771502320317096, 12225654.
26. Andoh T, Kishi H, Motoki K, Nakanishi K, Kuraishi Y, Muraguchi A. Protective effect of IL-18 on kainate- and IL-1β-induced cerebellar ataxia in mice. J Immunol 2008, 180:2322-2328.
27. Gardoni F, Boraso M, Zianni E, Corsini E, Galli CL, Cattabeni F, Marinovich M, Di Luca M, Viviani B. Distribution of interleukin-1 receptor complex at the synaptic membrane driven by interleukin-1β and NMDA stimulation. J Neuroinflammation 2011, 8:14. 10.1186/1742-2094-8-14, 3045339, 21314939.
28. Davis CN, Tabarean I, Gaidarova S, Behrens MM, Bartfai T. IL-1β induces a MyD88-dependent and ceramide-mediated activation of Src in anterior hypothalamic neurons. J Neurochem 2006, 98:1379-1389. 10.1111/j.1471-4159.2006.03951.x, 16771830.
29. Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 2010, 6:158-166. 10.1038/nrendo.2009.271, 20173777.
30. Zumsteg U, Reimers JI, Pociot F, Mørch L, Helqvist S, Brendel M, Alejandro R, Mandrup-Poulsen T, Dinarello CA, Nerup J. Differential interleukin-1 receptor antagonism on pancreatic β and α cells: studies in rodent and human islets and in normal rats. Diabetologica 1993, 36:759-766.
31. Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology (Oxford) 2012, 51(Suppl 6):vi5-vi9.
32. Stolina M, Bolon B, Dwyer D, Middleton S, Duryea D, Kostenuik PJ, Feige U, Zack DJ. The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis. Biomarkers 2008, 13:692-712. 10.1080/13547500802651911, 19096963.
33. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002, 13:323-340. 10.1016/S1359-6101(02)00020-5, 12220547.
34. Allan SM, Tyrrell PJ, Rothwell NJ. Interleukin-1 and neuronal injury. Nat Rev Immunol 2005, 5:629-640. 10.1038/nri1664, 16034365.
35. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010, 10:89-102.
36. Bao J, Yue T, Liu W, Zhang Q, Zhou L, Xu HJ, Dai SM. Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis. Clin Rheumatol 2011, 30:697-701. 10.1007/s10067-010-1654-5, 21221689.
37. Kaiser C, Knight A, Nordström D, Pettersson T, Fransson J, Florin-Robertsson E, Pilström B. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int 2012, 32:295-299. 10.1007/s00296-011-2096-3, 3264859, 21881988.
38. Jonville-Bera AP, Guilmot JL, Aspe G, Autret-Leca E, Magnant J. Is exogenous administration of IL-1ra (anakinra) likely to induce severe depression?. Eur J Clin Pharmacol 2011, 67:213-214. 10.1007/s00228-010-0915-1, 20941485.
39. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007, 356:1517-1526. 10.1056/NEJMoa065213, 17429083.
40. Wang D, Zhang S, Li L, Liu X, Mei K, Wang X. Structural insights into the assembly and activation of IL-1β with its receptors. Nat Immunol 2010, 11:905-911. 10.1038/ni.1925, 20802483.
41. Hegen M, Keith JC, Collins M, Nickerson-Nutter CL. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis 2008, 67:1505-1515. 10.1136/ard.2007.076430, 18055474.
42. Takao T, Tracey DE, Mitchell WM, De Souza EB. Interleukin-1 receptors in mouse brain: characterization and neuronal localization. Endocrinology 1990, 127:3070-3078. 10.1210/endo-127-6-3070, 2147409.
43. Yabuuchi K, Minami M, Katsumata S, Satoh M. Localization of type I interleukin-1 receptor mRNA in the rat brain. Brain Res Mol Brain Res 1994, 27:27-36. 10.1016/0169-328X(94)90180-5, 7877451.
44. Friedman WJ. Cytokines regulate expression of the type 1 interleukin-1 receptor in rat hippocampal neurons and glia. Exp Neurol 2001, 168:23-31. 10.1006/exnr.2000.7595, 11170718.
45. Huang Y, Smith DE, Ibáñez-Sandoval O, Sims JE, Friedman WJ. Neuron-specific effects of interleukin-1β are mediated by a novel isoform of the IL-1 receptor accessory protein. J Neurosci 2011, 31:18048-18059. 10.1523/JNEUROSCI.4067-11.2011, 3261076, 22159118.
46. Takeda K, Ichijo H. Neuronal p38 MAPK signalling: an emerging regulator of cell fate and function in the nervous system. Genes Cells 2002, 7:1099-1111. 10.1046/j.1365-2443.2002.00591.x, 12390245.
47. Pankratova S, Gu B, Kiryushko D, Korshunova I, Køhler LB, Rathje M, Bock E, Berezin V. A new agonist of the erythropoietin receptor, Epobis, induces neurite outgrowth and promotes neuronal survival. J Neurochem 2012, 121:915-923. 10.1111/j.1471-4159.2012.07751.x, 22469063.
48. Layé S, Parnet P, Goujon E, Dantzer R. Peripheral administration of lipopolysaccharide induces the expression of cytokine transcripts in the brain and pituitary of mice. Brain Res Mol Brain Res 1994, 27:157-162. 10.1016/0169-328X(94)90197-X, 7877446.
49. Enevoldsen MN, Kochoyan A, Jurgenson M, Jaako K, Dmytriyeva O, Walmod PS, Nielsen JD, Nielsen J, Li S, Korshunova I, Klementiev B, Novikova T, Zharkovsky A, Berezin V, Bock E. Neuroprotective and memory enhancing properties of a dual agonist of the FGF receptor and NCAM. Neurobiol Dis 2012, 48:533-545. 10.1016/j.nbd.2012.07.016, 22842016.
50. Klementiev B, Novikova T, Korshunova I, Berezin V, Bock E. The NCAM-derived P2 peptide facilitates recovery of cognitive and motor function and ameliorates neuropathology following traumatic brain injury. Eur J Neurosci 2008, 27:2885-2896. 10.1111/j.1460-9568.2008.06245.x, 18540884.
51. Klementiev B, Novikova T, Novitskaya V, Walmod PS, Dmytriyeva O, Pakkenberg B, Berezin V, Bock E. A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Aβ25-35. Neuroscience 2007, 145:209-224. 10.1016/j.neuroscience.2006.11.060, 17223274.
52. Meda L, Baron P, Prat E, Scarpini E, Scarlato G, Cassatella MA, Rossi F. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with β-amyloid25-35. J Neuroimmunol 1999, 93:45-52. 10.1016/S0165-5728(98)00188-X, 10378868.
53. Schiffenbauer J, Streit WJ, Butfiloski E, LaBow M, Edwards C, Moldawer LL. The induction of EAE is only partially dependent on TNF receptor signaling but requires the IL-1 type I receptor. Clin Immunol 2000, 95:117-123. 10.1006/clim.2000.4851, 10779405.
54. Martin D, Near SL. Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. J Neuroimmunol 1995, 61:241-245. 10.1016/0165-5728(95)00108-E, 7593560.
55. Pollak Y, Ovadia H, Orion E, Yirmiya R. The EAE-associated behavioral syndrome: II. Modulation by anti-inflammatory treatments. J Neuroimmunol 2003, 137:100-108. 10.1016/S0165-5728(03)00073-0, 12667653.
56. Badovinac V, Mostarica-Stojković M, Dinarello CA, Stošić-Grujičithomampersan S. Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. J Neuroimmunol 1998, 85:87-95. 10.1016/S0165-5728(98)00020-4, 9627001.